Abstract
Omeprazole (OMP) is effective in the treatment of gastric hyperacidity and is metabolized by CYP2C19 and CYP3A4. These enzymes are modulated by estrogen and progesterone which regulate the menstrual cycle. The variations in the pharmacokinetics (PK) of many drugs like amphetamine, benzodiazepines and caffeine have been reported during menstrual cycle. In present study, the PK of the omeprazole and its metabolites was investigated during various phases of the menstrual cycle. A single oral dose, open-label, non-controlled, pharmacokinetic study of omeprazole was conducted in healthy young/premenopausal females (n = 16). The PK of omeprazole, 5-hydroxy-omeprazole and omeprazole sulphone was evaluated in three phases of menstrual cycle. The blood samples were analyzed using reversed-phase HPLC coupled with UV detector and the PK data were evaluated. The activities of CYP2C19 and CYP3A4 were determined as AUCOH-OMP/AUCOMP and AUCOMP-SUL/AUCOMP, respectively. Omeprazole showed significantly (p < 0.05) higher \([{\text{AUC}} ]_{0}^{\infty }\) and CL/F in follicular and menstrual phases, respectively. The \([{\text{AUC}} ]_{0}^{\infty }\) of 5-hydroxy omeprazole was also significantly (p < 0.05) higher in follicular phase. The metabolic ratios (MR) of 5-hydroxy omeprazole and omeprazole sulphone were lower in follicular phase compared with the luteal phase. The present study suggests that high estrogen levels of follicular phase may result in increased absorption of omeprazole. The lower MR for 5-hydroxy omeprazole and omeprazole sulphone in follicular phase as compared to luteal phase suggests that metabolism of omeprazole is low in follicular phase as compared to luteal phase, which is progesterone-dominant phase. However, the clinical significance for these findings needs to be determined.
Similar content being viewed by others
Abbreviations
- PK:
-
Pharmacokinetics
- OMP:
-
Omeprazole
- 5-OH-OMP:
-
5-Hydroxy omeprazole
- OMP-SUL:
-
Omeprazole sulphone
- IS:
-
Internal standard
- MR:
-
Metabolic ratios
- P-gp:
-
P-glycoprotein
- PCR:
-
Polymerization chain reaction
- HOMZ PMs:
-
Homozygous poor metabolizers
- HOMZ EMs:
-
Homozygous extensive metabolizers
- HTRZ PMs:
-
Heterozygous poor metabolizers
References
Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:966–972
Aguwa CN (1984) Effects of exogenous administration of female sex hormones on gastric secretion and ulcer formation in the rat. Eur J Pharmacol 104:79–84
Ahmad L, Iqbal Z, Nazir S, Shah Y, Khan A, Khan MI, Nasir F, Khan A (2011) Optimization and validation of HPLC-UV method for simultaneous determination of omeprazole and its metabolites in human plasma: effects of various experimental conditions and parameters. J Liq Chromatogr Relat Technol 34:1488–1501
Brett S (2005) Science review: the use of proton pump inhibitors for gastric acid suppression in critical illness. Crit Care 9:45–50
Choi S-Y, Koh KH, Jeong H (2013) Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos 41:263–269
Datz FL, Christian PE, Moore J (1987) Gender-related differences in gastric emptying. J Nucl Med 28:1204
Ferraro R, Lillioja S, Fontvieille A-M, Rising R, Bogardus C, Ravussin E (1992) Lower sedentary metabolic rate in women compared with men. J Clin Investig 90:780
Golub S (1992) Periods: from menarche to menopause. Sage Publications, Newbury Park, CA
Hägg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173
Heitkemper M, Jarrett M, Bond EF, Chang L (2003) Impact of sex and gender on irritable bowel syndrome. Biolog Res Nurs 5:56–65
Muizzuddin N, Marenus KD, Schnittger SF, Sullivan M, Maes DH (2005) Effect of systemic hormomal cyclicity on skin. J Cosmet Sci 56:311–322
Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y (2006) Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 97:1198–1204
Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, Ingelman-Sundberg M (2010) Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol 78:886–894
Nelson LR, Bulun SE (2001) Estrogen production and action. J Am Acad Dermatol 45:S116–S124
Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S (2009) Genetic polymorphisms of CYP2D6* 10 and CYP2C19* 2,* 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115:952–961
Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg’s Arch Pharmacol 364:551–557
Pechère-Bertschi A, Burnier M (2004) Female sex hormones, salt, and blood pressure regulation&ast. Am J Hypertens 17:994–1001
Rodriguez I, Kilborn MJ, Liu X-K, Pezzullo JC, Woosley RL (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285:1322–1326
Shapiro AB, Fox K, Lam P, Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Eur J Biochem 259:841–850
Stachenfeld NS, Dipietro L, Palter SF, Nadel ER (1998) Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. Am J Physiol Regul Integr Comp Physiol 274:R187–R195
Terner JM, De Wit H (2006) Menstrual cycle phase and responses to drugs of abuse in humans. Drug Alcohol Depend 84:1–13
Van Beek E, Houben A, Van Es P, Willekes C, Korten E, De Leeuw P, Peeters L (1996) Peripheral haemodynamics and renal function in relation to the menstrual cycle. Clin Sci 91:163–168
White TL, Justice AJ, de Wit H (2002) Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729–741
Zhang Y, Kim M-J, Bertino JS, Nafziger AN, Sellers EM (2006) Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. J Clin Pharmacol 46:345–352
Acknowledgments
We are thankful to University of Peshawar for providing facilities and technical support to conduct the study. We pay special thanks to Astra Zeneca for providing us with metabolites of omeprazole.
Conflict of interest
No conflict of interest/financial exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nazir, S., Iqbal, Z., Ahmad, L. et al. Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle. Eur J Drug Metab Pharmacokinet 40, 13–22 (2015). https://doi.org/10.1007/s13318-013-0167-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-013-0167-4